Efficacy of Quetiapine for Pediatric Delirium

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Delirium

In brief

This study is designed to assess the safety and efficacy of quetiapine as treatment for pediatric delirium.

Key facts

Study ID

NCT02056171

Run by

Weill Medical College of Cornell University

People needed

6

Starts

2015-03-01

Expected to finish

2016-12-01

Last updated by the study team

2017-12-13

Who can join

Age: 1 and older, up to 22. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium

You may not qualify if…

• Age <1
• Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or unarousable).
• current treatment for alcohol withdrawal
• hepatic encephalopathy
• pregnancy
• diagnosis of major depressive disorder or bipolar disorder
• diagnosis of movement disorder
• diagnosis of diabetic ketoacidosis
• baseline QTc >500 milliseconds
• non-English speaking subjects and/or parent/guardian

Where it is running

• Columbia University Medical Center — New York, New York, United States
• NY Prebyterian Hospital/Weill Cornell Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.